We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+7.88%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4B
AUM Growth
-$191M
Cap. Flow
-$236M
Cap. Flow %
-5.9%
Top 10 Hldgs %
48.84%
Holding
128
New
18
Increased
19
Reduced
24
Closed
26

Top Buys

Rank Stock Value
1
CAI
Caris Life Sciences
CAI
+$81.8M
2
UNH icon
UnitedHealth
UNH
+$51.6M
3
ROIV icon
Roivant Sciences
ROIV
+$30.1M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$23.2M
5
JBIO
Jade Biosciences
JBIO
+$18.1M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$97.6M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$76.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$56.9M
4
SWTX
SpringWorks Therapeutics
SWTX
+$41.9M
5
TMO icon
Thermo Fisher Scientific
TMO
+$34.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.99%
2 Miscellaneous 1.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBLL
126
CeriBell Inc
CBLL
$911M
– –
-112,500
Closed -$2.16M
KMTS
127
Kestra Medical Technologies
KMTS
$1.5B
– –
-250,000
Closed -$6.23M
2 3 4 5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2025 Portfolio in Review

As of Q2 2025, OrbiMed held 128 positions worth $4B, down 4.5% from $4.19B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

OrbiMed withdrew a net $236M in Q2 2025, closing 26 positions and reducing 24 holdings. Its most notable exit was Pfizer, an estimated $97.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Caris Life Sciences worth $81.1M.

  • OrbiMed's largest Q2 2025 buy was Caris Life Sciences: 3,034,858 shares worth $81.1M.
  • OrbiMed added most to UnitedHealth in Q2 2025, an estimated $51.6M increase.
  • OrbiMed's biggest Q2 2025 reduction was Neurocrine Biosciences, cutting an estimated $56.9M.
  • OrbiMed fully exited Pfizer in Q2 2025, selling an estimated $97.6M.
  • OrbiMed's ten largest holdings make up 49% of its $4B portfolio in Q2 2025.
  • OrbiMed opened 18 new positions and closed 26 in Q2 2025.
  • OrbiMed's portfolio value fell 4.5% quarter-over-quarter to $4B.

Based on OrbiMed's 13F filing for Q2 2025, filed 14 Aug 2025.